Devonian Health Group (TSXV:GSD) ROCE % : -7.45% (As of Oct. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Devonian Health Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Devonian Health Group's annualized ROCE % for the quarter that ended in Oct. 2024 was -7.45%.

Devonian Health Group ROCE % Historical Data

The historical data trend for Devonian Health Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devonian Health Group ROCE % Chart

Devonian Health Group Annual Data

Trend

Jun15

Jun16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

ROCE %

Get a 7-Day Free Trial

-24.76

-19.36

-15.38

-24.22

-5.85

Devonian Health Group Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
ROCE %	Get a 7-Day Free Trial															-16.95	-33.42	-8.53	32.81	-7.45

Devonian Health Group ROCE % Calculation

Devonian Health Group's annualized ROCE % for the fiscal year that ended in Jul. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2024 )		(A: Jul. 2023 )		(A: Jul. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2024 )		(A: Jul. 2023 )		(A: Jul. 2024 )
	=	-0.845	/	( ( (19.177 - 4.857)	+	(30.733 - 16.146) )	/ 2 )
	=	-0.845	/	( (14.32	+	14.587)	/ 2 )
	=	-0.845	/	14.4535
	=	-5.85 %

Devonian Health Group's ROCE % of for the quarter that ended in Oct. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Oct. 2024 )		(Q: Jul. 2024 )		(Q: Oct. 2024 )
	=	-1.088	/	( ( (30.733 - 16.146)	+	(33.34 - 18.73) )	/ 2 )
	=	-1.088	/	( ( 14.587	+	14.61 )	/ 2 )
	=	-1.088	/	14.5985
	=	-7.45 %

(1) Note: The EBIT data used here is four times the quarterly (Oct. 2024) EBIT data.

Devonian Health Group (TSXV:GSD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Devonian Health Group ROCE % Related Terms

Thank you for viewing the detailed overview of Devonian Health Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Devonian Health Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (TSXV:GSD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DVHGF:USA

Address

360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1

Website

https://www.groupedevonian.com

Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.

Devonian Health Group Headlines

No Headlines